CN104706572A - Preparation method of dobutamine hydrochloride injection - Google Patents
Preparation method of dobutamine hydrochloride injection Download PDFInfo
- Publication number
- CN104706572A CN104706572A CN201310678436.1A CN201310678436A CN104706572A CN 104706572 A CN104706572 A CN 104706572A CN 201310678436 A CN201310678436 A CN 201310678436A CN 104706572 A CN104706572 A CN 104706572A
- Authority
- CN
- China
- Prior art keywords
- injection
- dobutamine hydrochloride
- preparation
- hydrochloric acid
- dobutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 229960001654 dobutamine hydrochloride Drugs 0.000 title claims abstract description 56
- 238000002347 injection Methods 0.000 title claims abstract description 41
- 239000007924 injection Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 21
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 14
- 229930182817 methionine Natural products 0.000 claims abstract description 14
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 13
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000008215 water for injection Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 3
- 229960001089 dobutamine Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 16
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000011835 investigation Methods 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 35
- 239000000047 product Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940093181 glucose injection Drugs 0.000 description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000014992 beta1-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006808 beta1-adrenergic receptor activity proteins Proteins 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method of an injection containing sodium pyrosulfite, methionine, sodium chloride, diluted hydrochloric acid, and dobutamine hydrochloride. According to the preparation method, sodium pyrosulfite and methionine are used as anti-oxidants; sodium chloride is taken as an isoosmotic adjusting agent and a stabilizing agent; and dilute hydrochloric acid is taken as a pH value conditioning agent. Quality of the dobutamine hydrochloride injection accords with requirements of <Chinese pharmacopoeia 2010>; and quality is stable after accelerated testing and long-term stability investigation.
Description
Technical field
The present invention relates to dobutamine hydrochloride formulation art, be specifically related to a kind of preparation method of dobutamine hydrochloride injection.
Background technology
Dobutamine hydrochloride injection is beta-2 adrenoceptor excitomotor.Main excitatory β 1 adrenoceptor, there is slight α effect, the vasorelaxation action of β 2 is had time heavy dose of, have positive inotropic and more weak Positive Chronotropic Action to cardiac muscle, energy activated adenyl cyclase, makes ATP be converted into c-AMP, promote that calcium ion enters cardiac cell membrane, thus enhancing myocardial contraction, increase cardiac output, reduce pulmonary capillary wedge pressure.This product can with the vasodilator conbined usage such as sodium nitroprusside.
Dobutamine hydrochloride injection vein injects onset in 1 ~ 2 minute, can extend to 10 minutes as slowly instiled, and the effect in latter 10 minutes of general quiet note reaches peak, and t1/2 is about 2 minutes.
Dobutamine hydrochloride injection is used for the treatment of the weak heart failure of myocardial contraction that various different reason causes, as the acute myocardial infarction pump failure that coronary heart disease causes, dilated cardiomyopathy, the heart failure that rheumatic valvular disease causes, LOS caused after cardiac operation under direct vision and refractory heart failure etc.
At present, the dosage form of dobutamine hydrochloride has powder pin, injection, transfusion.Dobutamine hydrochloride injection records in version " Chinese Pharmacopoeia " (two) in 2010.
" Chinese Pharmaceutical " the 12nd volume the 9th phase " Dobutamine Hydrochloride Glucose Injection Study on Preparation " in 2003 discloses the formulation and technology of Dobutamine Hydrochloride Glucose Injection, prescription consists of dobutamine hydrochloride, glucose, sodium sulfite, water for injection, and pH scope is 3.5 ~ 4.0; " Journal of Chinese Hospital Pharmacy " the 24th volume the 5th phase " Dobutamine Hydrochloride Glucose Injection prescription and Study on Preparation " in 2004 discloses the formulation and technology of Dobutamine Hydrochloride Glucose Injection, prescription consists of dobutamine hydrochloride, glucose, sodium sulfite, water for injection, and pH scope is 3.5 ~ 4.0; " northern pharmacy " the 7th volume the 5th phase " dobutamine hydrochloride injection formula and Study on Preparation " in 2010 discloses the formulation and technology of dobutamine hydrochloride injection, prescription composition comprises dobutamine hydrochloride, sodium sulfite, calcium disodium edetate, water for injection etc., and pH scope is 3.0 ~ 4.0.
In addition, Chinese patent 201110028874.4 discloses a kind of Dobutamine hydrochloride injection and preparation method thereof, comprising dobutamine hydrochloride 10.0 ~ 30.0g, cysteine hydrochloride 0.4 ~ 1.2mg, mannitol 10.0 ~ 30.0g, all the other are water for injection, and pH scope is 3.0 ~ 3.3.
Because dobutamine hydrochloride is slightly molten in water, dissolve in an acidic solution, need to add dilute hydrochloric acid to regulate, but find in preparation process, this product is to high light and high temperature instability, its aqueous solution room temperature is placed and is become red gradually, pH scope is to product stability, especially visible foreign matters is also had a significant impact, and the stability of the addition sequence of each component on product has impact, needs to regulate and control preparation process, for this reason, the present invention on the basis of existing technology, finds a kind of preparation method of effective dobutamine hydrochloride injection through research.
Summary of the invention
A kind of safe and reliable, stability is the object of the present invention is to provide better to be easy to the preparation method of the dobutamine hydrochloride injection produced.
In order to achieve the above object, dobutamine hydrochloride injection of the present invention, every 100ml contains following component:
Dobutamine hydrochloride (in dobutamine) 20g
Sodium pyrosulfite 0.05g
Methionine 0.05g
Sodium chloride 0.85g
Dilute hydrochloric acid 0.5ml
Water for injection adds to 100ml
Injection pH is 2.5 ~ 2.9
Described solution ph regulates with dilute hydrochloric acid.
The preparation method of injection of the present invention is as follows:
Dilute hydrochloric acid is joined in 70% water for injection (40 DEG C ~ 50 DEG C) and make hydrochloric acid solution, add dobutamine hydrochloride stirring and make to dissolve completely, add sodium pyrosulfite, methionine stirs and makes to dissolve completely, add sodium chloride stirring again to make to dissolve completely, regulate pH:2.5 ~ 2.9 with dilute hydrochloric acid, add to the full amount of water for injection and stir, add 0.05% activated carbon adsorption filtering decarbonization after 15 minutes, fine straining, embedding (inflated with nitrogen), 121 DEG C, 15 minutes water-bath sterilizations, lamp inspection, packaging, to obtain final product.
Whole preparation process inflated with nitrogen and lucifuge, sterilizing adopts rotary water bath sterilizing in 121 DEG C, 15 minutes, and this sterilizing methods more has sterility barrier than other sterilization, and make product safety reliable, the addition sequence of each component is also more reasonable, makes product more stable.
Dobutamine hydrochloride injection provided by the present invention has the following advantages:
(1) adopt methionine and sodium pyrosulfite conbined usage and add sodium chloride: due to cysteine hydrochloride, methionine and these amino acids antioxidant effects of glycine are not quite similar, it is generally acknowledged that aminoacid has antioxidant synergist effect more, facts have proved, antioxidant and antioxidant synergist merge and use, effectively can improve antioxidant effect, sodium pyrosulfite and methionine share than being used alone sodium pyrosulfite or being used alone cysteine hydrochloride, methionine, glycine has positive effect, sodium pyrosulfite and methionine share the stability that more can increase dobutamine hydrochloride injection, adding sodium chloride not only can regulate isotonic, and is conducive to the stability of dobutamine hydrochloride.
(2) we are found by great many of experiments, injection pH is excessive and too smallly all can affect principal agent stability in the solution, and when injection pH is 2.5 ~ 2.9, higher in 3.0 ~ 3.3 or 3.5 ~ 4.0 stability than pH, and what make dobutamine hydrochloride dissolve is better, more stable in put procedure, ensure that visible foreign matters conforms with the regulations before the deadline.
(3) the present invention finds, the stability of operating procedure on product has impact, particularly in preparation process, under violent operating condition, sample impurity is easily caused to increase, therefore the present invention proposes new operating procedure, first dobutamine hydrochloride is joined in hydrochloric acid solution, add sodium pyrosulfite and methionine again, finally add sodium chloride, than prior art dobutamine hydrochloride more can be made to dissolve complete, and form stable dobutamine hydrochloride solution, and dobutamine hydrochloride can be made to obtain antioxidant and the more effective protection of stabilizing agent in advance, effectively control the increase of related substance and visible foreign matters.
detailed description of the invention:
Describe content of the present invention by the following examples in detail, but embodiment is not construed as limiting the invention.
Embodiment
1, prescription
Dobutamine hydrochloride (in dobutamine) 20g
Sodium pyrosulfite 0.05g
Methionine 0.05g
Sodium chloride 0.85g
Dilute hydrochloric acid 0.5ml
Water for injection adds to 100ml
2, preparation method
The preparation method of injection of the present invention is as follows:
Dilute hydrochloric acid is joined in 70% water for injection (40 DEG C ~ 50 DEG C) and make hydrochloric acid solution, add dobutamine hydrochloride stirring and make to dissolve completely, add sodium pyrosulfite, methionine stirs and makes to dissolve completely, add sodium chloride stirring again to make to dissolve completely, regulate pH:2.5 ~ 2.9 with dilute hydrochloric acid, add to the full amount of water for injection and stir, add 0.05% activated carbon adsorption filtering decarbonization after 15 minutes, fine straining, embedding (inflated with nitrogen), 121 DEG C, 15 minutes water-bath sterilizations, lamp inspection, packaging, to obtain final product.
3, pilot project
Prepare three batches of dobutamine hydrochloride injection by the embodiment of the present invention, lot number is 20121016,20121017,20121018; Prepare a collection of dobutamine hydrochloride injection by existing Chinese patent, lot number is: 20121019, Quan Jian simultaneously, and does to accelerate and long-time stability investigation.
3.1 examine entirely
By the inspection of " Chinese Pharmacopoeia 2010 " year version two dobutamine hydrochloride injection quality standards, the results are shown in Table 1, table 2, table 3, table 4.
Table 1 lot number 20121016 testing result
Table 2 lot number 20121017 testing result
Table 3 lot number 20121018 testing result
Table 4 lot number 20121019 testing result
Check conclusion: four batches of dobutamine hydrochloride injection are by two inspections of " Chinese Pharmacopoeia " version in 2010, and result all conforms with the regulations.
3.2 accelerated test
Get four batches of dobutamine hydrochloride injection of above-mentioned preparation, be placed in 40 DEG C ± 2 DEG C respectively, place six months under the accelerated test condition of 75% ± 5%RH, respectively at sampling at the 0th, 1,2,3,6 the end of month, investigate the change of its character, acidity, visible foreign matters, related substance, content aspect, testing inspection the results are shown in Table 5.
Table 5 accelerated test result
After the accelerated test of 6 months, experimental result shows that the dobutamine hydrochloride injection prepared by the present invention is more assorted than the dobutamine hydrochloride injection related substance list standby by existing patent system and total assorted all low, and it is also little to increase ratio, content declines also much smaller, visible foreign matters has significant difference, illustrates that dobutamine hydrochloride injection prepared by the present invention dobutamine hydrochloride injection stability more standby than existing patent system is significantly increased.
4, long term test
Get four batches of dobutamine hydrochloride injection of above-mentioned preparation, put 25 DEG C ± 2 DEG C, place 12 months under the condition of 60% ± 10%RH, respectively at sampling at the 0th, 3,6,9,12 the end of month, investigate the change of its character, acidity, visible foreign matters, related substance, content aspect, testing inspection the results are shown in Table 6.
Table 6 long-term test results
After the long term test of 12 months, experimental result shows that the dobutamine hydrochloride injection prepared by the present invention is more assorted than the dobutamine hydrochloride injection related substance list standby by existing patent system and total assorted all low, and it is also little to increase ratio, content declines also much smaller, visible foreign matters has significant difference, illustrates that dobutamine hydrochloride injection prepared by the present invention dobutamine hydrochloride injection stability more standby than existing patent system is significantly increased.
3. conclusion (of pressure testing)
Above result of the test shows, dobutamine hydrochloride injection prepared by the present invention is under the condition accelerated and place for a long time, and drug content is high, and its related substances is low, and visible foreign matters conforms with the regulations, and the stability shown significantly improves than prior art.
Claims (1)
1. a preparation method for dobutamine hydrochloride injection, is characterized in that described injection 100ml contains following component:
Dobutamine hydrochloride (in dobutamine) 20g
Sodium pyrosulfite 0.05g
Methionine 0.05g
Sodium chloride 0.85g
Dilute hydrochloric acid 0.5ml
Water for injection adds to 100ml
Injection pH is 2.5 ~ 2.9
Its preparation method is as follows:
Dilute hydrochloric acid is joined in 70% water for injection (40 DEG C ~ 50 DEG C) and make hydrochloric acid solution, add dobutamine hydrochloride stirring to make to dissolve completely, add the stirring of sodium pyrosulfite, methionine and sodium chloride again to make to dissolve completely, regulate pH2.5 ~ 2.9 with dilute hydrochloric acid, add to the full amount of water for injection and stir, add 0.05% activated carbon adsorption filtering decarbonization after 15 minutes, fine straining, embedding (inflated with nitrogen), 121 DEG C, 15 minutes water-bath sterilizations, pack and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310678436.1A CN104706572A (en) | 2013-12-14 | 2013-12-14 | Preparation method of dobutamine hydrochloride injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310678436.1A CN104706572A (en) | 2013-12-14 | 2013-12-14 | Preparation method of dobutamine hydrochloride injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104706572A true CN104706572A (en) | 2015-06-17 |
Family
ID=53406622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310678436.1A Pending CN104706572A (en) | 2013-12-14 | 2013-12-14 | Preparation method of dobutamine hydrochloride injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104706572A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906515A (en) * | 2015-12-10 | 2016-08-31 | 菏泽市方明制药有限公司 | Dobutamine hydrochloride decoloration technology |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013274A1 (en) * | 1992-12-10 | 1994-06-23 | Abbott Laboratories | Stabilized catecholamine solutions |
| CN102085180A (en) * | 2011-01-26 | 2011-06-08 | 蚌埠丰原涂山制药有限公司 | Dobutamine hydrochloride injection and preparation method thereof |
| CN103156809A (en) * | 2011-12-18 | 2013-06-19 | 山东方明药业集团股份有限公司 | Furosemide injection and preparation method thereof |
| CN103156807A (en) * | 2011-12-12 | 2013-06-19 | 山东方明药业集团股份有限公司 | Buflomedilhydroc hloride injection and preparation method thereof |
-
2013
- 2013-12-14 CN CN201310678436.1A patent/CN104706572A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013274A1 (en) * | 1992-12-10 | 1994-06-23 | Abbott Laboratories | Stabilized catecholamine solutions |
| CN102085180A (en) * | 2011-01-26 | 2011-06-08 | 蚌埠丰原涂山制药有限公司 | Dobutamine hydrochloride injection and preparation method thereof |
| CN103156807A (en) * | 2011-12-12 | 2013-06-19 | 山东方明药业集团股份有限公司 | Buflomedilhydroc hloride injection and preparation method thereof |
| CN103156809A (en) * | 2011-12-18 | 2013-06-19 | 山东方明药业集团股份有限公司 | Furosemide injection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 徐少民,吴双俊: "盐酸多巴酚丁胺注射液处方及制备工艺研究", 《北方药学》 * |
| 陈瑞杰,等: "盐酸多巴酚丁胺葡萄糖注射液处方与制备工艺研究", 《中国医院药学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906515A (en) * | 2015-12-10 | 2016-08-31 | 菏泽市方明制药有限公司 | Dobutamine hydrochloride decoloration technology |
| CN105906515B (en) * | 2015-12-10 | 2018-03-13 | 菏泽市方明制药有限公司 | A kind of dobutamine hydrochloride decoloration process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lawand et al. | Amino acid release into the knee joint: key role in nociception and inflammation | |
| CN105663106A (en) | Materials and methods for improving gastrointestinal function | |
| BR112020019192A2 (en) | PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS DEOXICOLIC ACID | |
| CN107441038B (en) | Ornithine aspartate injection and preparation method thereof | |
| TW202247842A (en) | Eye drop composition for preventing or treating ophthalmic diseases and preparation method thereof | |
| BR112013005763A2 (en) | injection of 5 - androstane-3b, 5, 6b-triol and method for preparation of injection | |
| CN104706572A (en) | Preparation method of dobutamine hydrochloride injection | |
| CN102872462B (en) | Ambroxol hydrochloride composition and preparation thereof | |
| CN106137979A (en) | A kind of lyophilized injectable powder and preparation method thereof | |
| CN118403008A (en) | Vitamin B6 injection and preparation method thereof | |
| CN104069063B (en) | Fasudic hydrochloride pharmaceutical composition and preparation method thereof | |
| CN100560068C (en) | The preparation method of levosulpiride injection | |
| CN102512360B (en) | Torasemide pharmaceutical composition with stabilization and safety for injection | |
| CN101450051B (en) | Monomer salvianolic acid B injection and preparation method thereof | |
| CN101491495B (en) | Salvianolic acid B magnesium injection, preparation method and use thereof | |
| CN101554370B (en) | Syringin for injection, preparation method and application thereof | |
| CN103784438B (en) | A kind of Amino Acid Compound Injection-HBC composition and method of making the same | |
| WO2014059363A1 (en) | Oral solution formulations of aripiprazole | |
| CN111388429A (en) | Freeze-dried powder injection of broad-spectrum antiviral drug Triazavirin and preparation method thereof | |
| CN103768055B (en) | Injection etomidate composition and method of making the same | |
| TWI857310B (en) | Ketorolac tromethamine liquid composition, preparation method and use thereof | |
| CN107157924A (en) | Naproxen sodium sodium chloride injection and preparation method thereof | |
| CN104997728A (en) | Nalmefene hydrochloride injection medicinal composition and preparation method thereof | |
| CN1853626B (en) | Zinc sulfate freeze-dried preparation for injection | |
| CN108158989B (en) | Ambroxol hydrochloride injection composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150617 |